Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2026-11-20
Target enrollment:
Participant gender:
Summary
Evaluating the efficacy and safety of irinotecan liposome injection in combination with Sintilimab in the second-line treatment of progressive gastric cancer